PMPRB Summary of VCUs & Orders - 2006
Click on medicine to view details of VCU
| DATE OF APPROVAL |
MEDICINE |
PATENTEE |
%Above Guidelines |
PRICE REDUCTION1 |
EXCESS REVENUES2 |
PAYMENTS |
PATENT STATUS |
| VCUs |
| July 14, 2006 |
Eloxatin |
sanofi-aventis Canada Inc. |
|
Yes |
$1,767,078.84 |
$1,767,078.846 |
Expiration 06/2019 |
| July 14, 2006 |
Hextend |
Hospira Healthcare Corporation (Canada) |
40 |
Yes |
$8,823.60 |
$8,823.60 |
Expiration 06/2014 |
| June 20, 2006 |
NuvaRing |
Organon Canada Ltd |
Yes |
Yes |
$115,584.93 |
$115,584.93 |
Expiration 03/2018 |
| Apr. 8, 2006 |
DukoralTM |
sanofi pasteur Limited |
Yes |
|
$74,073.32 7 |
$74,073.32 |
Expiration 06/2016 |
| ORDER |
1.There are no price reductions in cases where the PMPRB's jurisdiction ceased with the expiry or the dedication (prior to 1995) of the patent.
2. In all cases, all excess revenues were offset through further price reduction and/or payment.
7. Excess revenues for the period of July 1 - December 31, 2005, as per the VCU of December 15, 2005.